Cardiovascular Flashcards

1
Q

what layer does the cardiovascular system develop from in gastrulation

A

mesoderm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what forms in cardiac looping during embryonic development

A

2 bulges form; bulbus cordis and primordial ventricle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the 3 sources of blood flow to the embryonic heart

A

Vitelline Veins
Umbilical veins
Common cardinal veins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the 4 stages of cardiac septation in the atria

A

Septum primum forms and grows downwards
Foramen primum ‘space’ formed
Foramen secumdum forms in septum primum
Septum secundum begins to form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is the foramen ovale

A

hole in the atrial septa that permits oxygen-rich blood to move from RA – LA (shunting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what does the foramen ovale form in adults

A

fossa ovalis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is a patent foramen ovale

A

Abnormal resorption of septum primum during formation of foramen secundum
Results in short septum primum and therefore foramen ovale is still open after birth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

3 types of congenital heart defects

A

Transposition of the great arteries
Rare but very serious – pulmonary artery and aorta are swapped over
Truncus arteriosus
Rare but very serious – pulmonary artery and aorta don’t develop and remain as single vessel
Patent ductus arteriosus
Connection between pulmonary artery and aorta in the fetus – remains open after birth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the 3 layers of blood vessels

A

tunica intimida
tunica media
tunica adventitia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the 2 layers of the pericardium

A

Fibrous (outer layer)

serous (inner layer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are the functions of the pericardium

A

Fixation within mediastinum
Prevents over filling of heart
Lubrication (thin fluid film reduces friction)
Protection from infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

innervation of the pericardium

A

Phrenic nerve (C 3, 4 & 5)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the pericardial sinuses

A

Transverse pericardial sinus

Oblique pericardial sinus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the layers of the heart wall

A
  • Endocardium
  • Subendocardial Layer
  • Myocardium
  • Subepicardial Layer
  • Epicardium (Visceral Pericardium)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

the right atrium - anatomy

A
Receives blood from Superior &
Inferior Vena Cavae, Coronary Veins
• Right auricle
• 2 distinct parts divided by Crista
Terminalis
• Coronary sinus (between IVC & right
atrioventricular orifice)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

the right ventricle - anatomy

A
Receives blood from RA
• Pumps blood to pulmonary artery
via pulmonary orifice
• Triangular shape
• Anterior heart border
• Inflow and outflow portions
• Separated by supraventricular crest
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

the left atrium - anatomy

A
Receives blood from pulmonary
veins
• Forms posterior border (base) of
heart
• Left auricle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

the left ventricle - anatomy

A
  • Receives blood from left atrium
  • Forms apex of the heart
  • Left & inferior heart borders
  • Inflow & outflow portions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

heart valves function

A
Ensure blood flow in one
direction
• Connective tissue & lined in
endocardium
• 4 heart valves -
 2 atrioventricular
 2 semilunar
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

atrioventricular valves

A
Close at start of systole (first
heart sound)
• Valves are supported by chordae
tendineae
- tricuspid - right side
- mitral - left side
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

semi-lunar valves

A
Close at the start of diastole
(second heart sound)
• Found between ventricles &
corresponding outflow tracts
• Sinuses
• Lunule (thickened free edge)
• Nodule (widest area)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

auscultating heart sounds

A
First heart sound - start of systole
• Tricuspid valve
• Mitral valve
Second heart sound - START of diastole
• Aortic valve
• Pulmonary valve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

coronary circulating - arteries

A
Vessels that supply & drain the
heart
• 2 main arteries
  -  Right & left coronary arteries
• Left coronary artery
- Left anterior descending a.
- Left marginal a.
- Left circumflex a.
• Right coronary artery
- Right marginal a.
- Posterior interventricular a. (85%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Coronary Circulation – Venous drainage

A
Venous drainage of myocardium
• 5 tributaries
- Great cardiac v.
- Small cardiac v.
- Middle cardiac v.
- Left marginal v.
- Left posterior ventricular v.
.  Converge at coronary sinus
• Drain into RA between atrioventricular
orifice & orifice of IVC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

the sequence of events with each heart beat

A

1) Flow into atria, continuous except when they
contract. Inflow leads to pressure rise.
2) Opening of A-V valves - Flow to ventricles.
3) Atrial systole - completes filling of ventricles.
4) Ventricular systole (atrial diastole). Pressure rise
closes A-V valves, opens aortic and pulmonary
valves.
5) Ventricular diastole – causes closure of aortic and
pulmonary valves.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

cardiac output

A

Cardiac output is the volume blood pumped
per minute (by each ventricle).
Cardiac output = Heart rate x Stroke volume
At rest C.O. = 5 l/min
In exercise > 25 l/min as heart rate increases
2-3 fold and stroke volume increases 2 fold.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

stroke volume dependant on

A

a) Contractility (the force of contraction).
e.g. adrenaline ↑force, ↑stroke volume.
b) End diastolic volume (volume of blood
in ventricle at the end of diastole).
Force is stronger the more muscle fibres are
stretched (within limits):
Frank - Starling Mechanism or Starling’s Law of the Heart
Stroke volume ∝ Diastolic Filling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Frank-Starling Mechanism

A
Also known as the Preload.
Important in:
a)ensuring the heart can deal with wide variations in
venous return.
b)balancing the outputs of the two
sides of the heart
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

peripheral resistance - afterload

A

Resistance to blood flow away from the heart -
altered by dilation or constriction of blood
vessels (mainly pr-ecapillary resistance
arteries).
Cardiac Output = Blood pressure /
Peripheral Resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

summary of excitation pathway

A
Sinus rhythm = heart rate controlled by
S.A. node, rest rate approx. 72 beats/min
(wide variation).
• Action potential then activates atria.
• Atrial A.P. activates A.-V. node.
• A.V. node - small cells, slow conduction
velocity - introduces delay of 0.1 sec.
• A.V. node activates Bundle of His /
Purkinje fibres.
• Purkinje fibres activate ventricles.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

cardiac muscle

A

‘myogenic’ – it generates its own action potentials.
Action potentials develop spontaneously at the
sino-atrial node.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

SA node action potential

A
Pacemaker potential due to:↑gCa,↑gNa,↓gK
Action potential upstroke due to: ↑gCa
Repolarisation due to: ↑ gK, ↓ gCa
Noradrenaline - ↑gCa
Acetyl choline - ↑ gK, ↓ gCa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

cardiac v skeletal muscle cells

A

1- neurogenic v myogenic
2-longer cardiac action potential (with plateau)
3-Action potential controls duration of contraction in heart.
4-Ion currents during action potential
– skeletal ‘simple’, cardiac complex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

currents responsible for cardiac action potential

A
Depolarisation 
- large gNa
Plateau 
- small gNa
 - increase gCa
 - decrease gK
Repolarisation
 - decrease gCa
 - increase gK
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

source of Ca for contraction in cardiac muscle cells

A

Ca is released from the sarcoplasmic reticulum but
for heart cells Ca entry from outside is needed (‘Ca
induced Ca release’).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

the mechanisms of ECG

A

Electrical impulse (wave of depolarisation) picked up by
placing electrodes on patient
 The voltage change is sensed by measuring the current
change
 If the electrical impulse travels towards the electrode
this results in a positive deflection
 If the impulse travels away from the electrode this
results in a negative deflection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

types of ecg leads

A
coronal plane (limb leads)
-bipolar leads - I, II, III
-unipolar leads - aVL, aVR, aVF
transverse plane
-chest leads , v1-v6
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

whats the paper speed in an ecg

A

25mm per second
 Therefore one large box (5mm) corresponds to
0.2 seconds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

causes of P QRS T ecg waves

A
P wave caused by atrial
depolarization
QRS complex caused by
ventricular depolarization
T wave results from
ventricular repolarization
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

intervals between ecg waves

A
PR = 0.12-0.20sec
QRS = <0.12s
QTc = <0.440s (m), 0.460s (f)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

what does the PR interval tell us

A

the time to conduct through AVN/His

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

what does the QRS interval tell us

A
time for
ventricular depolarisation
 Patterns of conduction disease
though Bundles
 RBBB, LBBB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

what does the ST segment tell us

A
start of
ventricular repolarisation
(should be isoelectric)
    ST elevation 
acute infarction
 Other things pericarditis,
repolarisation abnormalities
     ST depression
 Ischaemia, LV strain (LVH)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

what does the T wave tell us

A

ventricular depolarisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

right bundle branch block - RBBB

A
- RBBB in V1 
 no change in initial impulse travel
  small r wave impulse depolarizes
LV by itself since RBBB (s wave)
 RV depolarized late by impulse thru muscle (r’ wave
 Hence RSR’ pattern (‘M’ shape)
‘MaRRoW’ pattern
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

left bundle branch block - LBBB

A
 LBBB in V1
 initial deflection altered since
travels right to left now
 Q wave/ negative deflection
 RV depolarizes unopposed
 may produce small r wave
 travels across septum to depolarize LV
 deep S wave
 W pattern in V1
‘WiLLiaM’ pattern
 ** note if patient has LBBB then
ST segments is uninterpretable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

calculating regular HR

A

Count the number of large squares between R waves (RR
interval)
 Rate = 300 divided by number of large squares between R waves
 Example: if RR interval = 4 large squares
 Heart rate = 300/4 = 75 beats per minute

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

calculating irregular HR

A

Use rhythm strip at the bottom of 12-lead ECG
 Rhythm strip is a 10 second recording of the heart
 Therefore, Rate = number of QRS complexes multiplied by 6
 Example: if number of QRS complexes = 13
 Heart rate = 13 X 6 = 78 beats per minute

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

bradyarrhythmia

A

Any abnormality of cardiac rhythm resulting in a slow heart
rate (heart block, slow AF) (c.f. sinus brady)
 HR < 60bpm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

tachyarrhythmia

A

Any abnormality of cardiac rhythm resulting in a fast heart
rate (SVT, uncontrolled AF/ Flutter, VT) (c.f. sinus tachy)
 HR > 100bpm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

first degree AV block

A
  • Regular Rhythm
  • PR interval > .20 seconds and is CONSTANT
  • Causes: IHD, conduction system disease, seen in healthy children or athletes
  • Usually does not require treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

second degree AV block / Mobitz I

A

Irregular Rhythm
• PR interval continues to lengthen until a QRS is missing (non-conducted sinus beat)
• PR interval is NOT CONSTANT
• Rhythm is usually benign unless associated with underlying pathology, (i.e. MI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

second degree AV block / Mobitz II

A
  • Irregular Rhythm
  • QRS complexes may be wide (greater than .12 seconds)
  • Non-conducted sinus impulses appear at irregular intervals
  • Rhythm is somewhat dangerous as the block is lower in the conduction system (BB level)
  • May cause syncope or may deteriorate into complete heart block (3rd degree block)
  • It’s appearance in the setting of an acute MI identifies a high risk patient
  • Cause: IHD, fibrosis of the conduction system
  • Treatment: pacemaker
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

3rd degree AV block (complete heart block)

A

Atria and ventricles beat independent of one another (AV dissociation)
• QRS’s have their own rhythm, P-waves have their own rhythm
• May be caused by inferior MI and it’s presence worsens the prognosis
• Treatment: usually requires pacemaker +/- temporary pacing/ isoprenaline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

narrow complex tachycardia

A

(QRS duration <0.12 s)
 Uncontrolled (ie “fast”) Atrial Fibrillation or Flutter
 Atrial tachycardia
 AVNRT/ AVRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

broad complex tachycardia

A

(QRS duration >0.12 s)
 Ventricular tachycardia
 Ventricular fibrillation
 **Is rhythm from above AVN with BBB/aberrancy??

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

physiological causes of arrhythmia

A

automacity increase

re-entry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

digoxin

A

INOTROPIC AGENT
used for Atrial fibrillation and heart failure
works on Na/K ATPase
increases ventricular contractibility
decreases conduction through AV node
side effect - anorexia, nausea, AV block,
visual problems,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

atenolol

A

used for AF, hypertension, angina
beta-blocker (relatively beta 1 selective)
decrease sympathetic NS activity (B1) at heart
decrease conduction system
decrease ventricular response rate
side effects, lethargy, hypotension, bronchospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

supraventricular tachycardia treatment

A

vagal stimulation - carotid massage, eyeball pressure…

drugs - adenosine (short acting purine), verapamil (calcium channel blocker)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

ventricular tachycardia treatment

A
lidocaine (rarely used) - class I anti-arrhythmic 
blocks Na channels in excitable tissues, decreases excitability and cardiac conduction, effects CNS (drowsiness, confusions...) 
amiodarone - class III anti-arrhythmic
blocks K channels, prolong cardiac action potential, TOXICITY
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

biomarkers of myocardial injury

A
total creatine kinase
myoglobin
CK-MB
lactate dehydrogenase (LDH)
cardiac troponin - TnT, TnI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

role of natriuretic peptides (BNP and ANP)

A

counter vasoconstriction

oppose renal salt and H2O retention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

risk factors for thrombus

A

hyper coagulability
abnormal blood flow
endothelial injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

different types of thrombi

A

mural thrombi - on the walls of spacious cavities -eg aorta
arterial thrombi - may be mural or occlusive - eg in coronary, carotid, cerebral, femoral
venous thrombi - phlebothrombosis, - eg, pelvis and leg veins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

what are lines of Zahn

A
in thrombi 
alternating pale(fibrin and platelets) and dark(RBC) lines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

different types of embolism

A

arterial - away the heart
venous - towards from the heart
superficial - saphenous system
deep - may be asymptomatic until embolised in lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

thrombus

A

A thrombus is a solidification of blood constituents that

forms within the vascular system during life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

embolism

A

An embolus is a detached intravascular solid,
liquid, or gaseous mass that is carried by the
blood to a site distant from its point of origin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

types of embolism

A
Pulmonary embolism
• Systemic embolism
• Amniotic fluid embolism
• Air embolism
• Fat embolism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

paradoxical embolism

A

In the presence of an interatrial or interventricular
defect, embolisms may gain access to the systemic
circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

systemic embolism

A

This term refers to emboli that travel through
the systemic arterial circulation
arise mostly from thrombi within the heart
almost always cause infarction in eg
-lower extremities
-the brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

infarct defintion

A

• Is an area of ischaemic necrosis caused by
occlusion of arterial supply or venous drainage in a
particular tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

necrosis definition

A

Refers to a spectrum of morphological changes that
follow cell death in living tissue, largely resulting
from the progressive action of enzymes on the
lethally injured cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

causes of infarction

A
• Thrombosis and thromboembolism account
for the vast majority
• Other causes include:
• Vasospasm
• Expansion of atheroma
• Compression of a vessel
• Twisting of the vessels through torsion
• Traumatic rupture
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

types of infarct

A
Red (haemorrhagic):
• Venous occlusion e.g. torsion
• Loose tissues
• Tissues with a dual circulation e.g. lung
     White (anaemic):
• Arterial occlusions
• Solid organs e.g. heart, spleen
      Septic
• Infected infarcts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

what are the 2 blood circulations

A

pulmonary - low pressure

systemic - high pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

primary systemic hypertension

A
idiopathic 
     Risk factors
• Genetic susceptibility
• High salt intake
• Chronic stress (excessive sympathetic activity)
• Abnormalities in renin/angiotensin-aldosterone
• Obesity
• Diabetes mellitus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

secondary systemic hypertension

A
Renal disease
• Chronic renal failure
• Polycystic kidneys
     Endocrine causes
• Pituitary - ACTH
• Adrenal cortex - glucocorticoid; mineralocorticoid
• Adrenal medulla - catecholamines
     Drug treatment e.g. steroids
     Others e.g. coarctation of the aorta
      Potentially treatable
• Careful clinical assessment
• Test the urine!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

systemic hypertension effects on the heart

A
Left ventricular hypertrophy
• Fibrosis
• Arrhythmias
• Coronary artery atheroma
• Ischaemic heart disease
• Cardiac failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

systemic hypertension effects on the kidney

A

• Nephrosclerosis
• ‘Drop-out’ of nephrons due to vascular narrowing
• Proteinuria
• Chronic renal failure
• Malignant hypertension is associated with acute
renal failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

vascular changes in systemic hypertension

A
Benign hypertension
• Acceleration of atherosclerosis
• Intimal proliferation and hyalinisation of
arteries and arterioles
 Malignant hypertension
• Fibrinoid necrosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

ischaemic heart disease

A
Blood supply to the heart is insufficient for its
metabolic demands
• Deficient supply
• Coronary artery disease (commonest)
• Reduced coronary artery perfusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

coronary artery disease

A

Coronary blood flow is normally independent of
aortic pressure
• Initial response to narrowing is autoregulatory
compensation
• >75% occlusion leads to ischaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

myocardial infarction

A

• An area of necrosis of heart muscle resulting
from reduction (usually sudden) in coronary
blood supply
• Due to
• Coronary artery thrombosis
• Haemorrhage into a coronary plaque
• Increase in demand in the presence of ischaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

chronic ischaemic heart disease

A

Chronic angina
• Exercise-induced chest pain
• Heart failure
• Related to reduced myocardial function
• Usually widespread coronary artery atheroma
• Areas of fibrosis often present in the myocardium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

cardiac failure

A

• Failure of the heart to pump sufficient blood to
satisfy metabolic demands
• Leads to underperfusion which causes fluid
retention and increased blood volume
• Two different, but linked, circulations
• Systemic
• Pulmonary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

left ventricular failure general info

A

• Dominates hypertensive and ischaemic heart
failure
• Causes pulmonary oedema, with associated
symptoms
• Leads to pulmonary hypertension and,
eventually, right ventricular failure
• Combined left and right ventricular failure is
often called ‘congestive’ cardiac failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

right ventricular failure CAUSES

A

• Secondary to left ventricular failure
• Related to intrinsic lung disease – ‘cor’ pulmonale
e.g. chronic obstructive pulmonary disease (COPD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

forward heart failure

A
  • Reduced perfusion of tissues

* Tends to be more associated with advanced failure

91
Q

backward heart failure

A

Due to increased venous pressures
• Dominated by fluid retention and tissue congestion
• Pulmonary oedema (left ventricular failure)
• Hepatic congestion and ankle oedema (right ventricular
failure)

92
Q

left failure clinical features

A
  • Hypotension
  • Pulmonary oedema
  • Paroxysmal nocturnal dyspnoea
  • Orthopnoea
  • Breathlessness on exertion
  • Acute pulmonary oedema with production of frothy fluid
93
Q

right failure clinical features

A

Right ventricular failure
• Ankle swelling
• Hepatic congestion (may be painful)

94
Q

cardiac preload

A

Volume of blood in the ventricles at the end of diastole.

determined by - 
- blood volume
- venous ‘tone’,
capacity of the
venous circulation to
hold blood
95
Q

what increases cardiac preload

A
  • Sympathetic NS activation
  • renal failure
  • heart failure
96
Q

cardiac afterload

A

Resistance the heart
must overcome to
circulate blood

determined by -
tone in arterial circulation

97
Q

what increases cardiac afterload

A
  • SNS activation

* hypertension

98
Q

what does vascular endothelium regulate

A
• blood vessel tone
• permeability
• leukocyte adhesion,
platelet aggregation
&amp; tendancy for thrombus
formation
99
Q

causes of endothelial dysfunction

A

§ elevated and modified low density lipoprotein e.g.
in familial hypercholesterolaemia
• oxygen free radicals caused by smoking, hypertension, activated inflammatory cells
• infectious microorganisms:
herpes virus, Chlamydia pneumoniae, H.pylori
• physical damage and gene activation by turbulent flow, high blood pressure
diabetes, ageing, being male!

100
Q

foam cells

A

macrophages take up LDL oxidised by interaction with oxygen free radicals

101
Q

statins

A

eg - simvastatin

  • lower cholesterol and LDL
  • inhibit HMG CoA reductase
  • increase expression of LDL receptors
102
Q

fibrates

A

eg - bezafibrate, gemfibrozil, fenofibrate

  • activate intracellular PRAR (alpha)
  • decrease circulating VLDL and triglyceride, small effect on LDL, increase HDL
103
Q

ezetimibe

A

lowers cholesterol absorption from small intestine via action in epithelial cells

104
Q

angina pectoris

A

intermittent chest pain caused by mismatch between
demand of oxygen by the heart and supply of oxygen
to the heart

105
Q

nitrates

A

eg - glycerol trinitrate (sub-lingual, rapid acting- leads to tolerance), iosorbide ditrinitrate (oral, long-lasting)
VEINS
- dilate veins, decrease venous return and preload, reduce O2 demand
ARTERIOLES
- dilate and reduce afterload on heart, reduce O2 demand

106
Q

nicorandil

A

blood vessel dilation by opening ATP sensitive K+ channels in smooth muscle cells
has nitrate moiety (part)
reduces preload and afterload
dilates coronary arteries

107
Q

ivabradine

A

blocks ‘funny currents’ in SA node cells - reduces rate of spontaneous depolarisation during AP generation
reduce HR and O2 demand
less side effects than B-blockers

108
Q

calcium antagonist

A

eg - nifedipine, dilthiazem

  • prevent opening of voltage Ca2+ channels
  • reduce contractibility
  • reduce force of contraction and therefore O2 demand
109
Q

anti-platelet drugs

A

taken prophylactically to reduce risk of thrombus

  • cyclooxygenase inhibitor e.g. aspirin
    • irreversible inhibition of COX, prevents formation of TxA2 &
    platelet activation
  • P2Y12 inhibitor e.g.clopidogrel, ticagrelor
    • blocks effect of ADP and prevents platelet activation
  • thrombin-receptor antagonist e.g. voripaxar
    • prevent activation of PAR-1 receptors on platelets

risk - bleeding - new drugs are shorter acting or reversible

110
Q

anticoagulant drugs

A

prevent the formation of fibrin to stabilise platelet plug

  • intravenous - heparin
  • orally active - warfarin, rivaroxaban
111
Q

warfarin

A

anticoagulant
- orally active
- Common clinical indications
atrial fibrillation, the presence of artificial heart valves, deep venous thrombosis, pulmonary embolism and, occasionally, after myocardial infarction.

risks
• narrow optimal range, high risk of bleeding
• broken down in liver, enzymes induced by other drugs, environmental infuences
• blood levels must be checked regularly

112
Q

fibrinolysis - pro and anti

A

pro- (tissue plasminogen activator)

anti- (PAI-1, antiplasmin)

113
Q

fibrinolytic ‘clot busting’ drugs

A

to remove clot and restore blood flow
•most effective to reduce mortality if given immediately (<3h) after MI or stroke
• accelerates conversion of plasminogen to plasmin,
which degrades fibrin in thrombus
tissue plasminogen activator (tPA. Activase) or streptokinase
can cause bleeding (reverse by tranexamic acid)

114
Q

surgical vascular interventions

A

balloon angioplasty

stenting

115
Q

most common heart failure

A

impaired contractility and emptying of ventricle (HF with reduced ejection fraction, HFrEF)

116
Q

less common heart failure

A

impaired relaxation and filling of ventricle (HF with preserved ejection
fraction, HFpEF): growing recognition, more common in women, diabetes, mechanisms less understood

117
Q

common causes of heart failure

A

l Myocardial infarction: damage to heart muscle
after loss of blood supply due to ischaemic heart
disease
l Volume Overload: due to damage to heart valves or
increased plasma volume
l Pressure Overload: due to uncontrolled
hypertension & increased afterload
l Myocarditis :bacterial infection of myocardium
l Cardiomyopathy: inherited defect in muscle
structure influencing function

118
Q

heart failure - Inotropic agents

A

digoxin

dobutamine (B1 adrenoreceptor agonist iv for rapid response), increases HR and contractility

Provide support in acute heart failure, but results in
increased oxygen and energy demand so not helpful long term in chronic heart failure

119
Q

heart failure - drugs for renin-angiotensin system

A

renin inhibitor - aliskiren
ACE inhibitor - enalapril, lisinopril
AT receptor antagonist - losartan, valsartan

120
Q

renin-angiotensin-aldosterone-system (RAAS)

A

pressure detected in juxtaglomerular cells, close to the afferent arteriole, when pressure is low renin is secreted into plasma

renin converts angiotensinogen > angiotensin I

angiotensin-converting enzyme converts angiotensin I > angiotensin II

angiotensin II increases after-load

angiotensin II is converted to ALDOSTERONE in the adrenal cortex

aldosterone causes NA and H2O retention in renal tubules and increases blood volume and pre-load

121
Q

sympathetic nervous system

A
baroreceptor feedback 
>
sympathetic nervous system
>increased HR (B1 receptor)
>activate renin release
>smooth muscle constriction (a1 adrenoreceptor)
      - arteriolar constriction = increased afterload
       - venoconstriction =
increased venous return and preload
122
Q

heart failure - drugs that reduce blood volume and preload

A

loop diuretics - frusemide, bumetamide
- impair Na+/K+/CL- readsorption in ascending loop of Henle

mineralocortoid receptor antagonists - spironolactone, eplerenone
- block effects of aldosterone on Na/K readsorption

123
Q

herat failure - drugs that affect the sympathetic NS

A

beta adrenoreceptor antagonists - atenolol, metoprolol (B1 selective)

reduce sympathetic drive to the heart (reduce O2 demand)

block renin release from kidney > decrease RAAS activation, decrease pre-load and after-load

few side effects - but not useful in asthmatics

124
Q

heart failure - vasodilators

A

nitrovasodilators - isosorbide mononitrate (long acting, risk of tolerance)
- venous circulation > decrease venous return and preload arterioles - reduce PVR and afterload

hydralazine
dilators that target arteries > veins and reduce afterload

used for acute and chronic heart failure

125
Q

structural changes in heart failure

A

aldosterone leads to fibrosis

AngII leads to hypertrophy

126
Q

what are lipids

A

organic compounds: poorly soluble in water but miscible in organic solvents

127
Q

important lipids in human physiology

A
steroids - cholesterol, hormones
fat soluble vitamins-A D E K
phospholipids 
sphingolipids
triglycerides
128
Q

lipoproteins

A

Transport cholesterol & triglycerides around the body via the circulation

types
-chylomicrons
-VLDL
-IDL
LDL
HDL
129
Q

Where are lipoproteins created

A
  • small intestine - dietary lipids
  • liver - endogenous lipids

formed in the epithelium of the gut and synthesised in liver

130
Q

3 main pathways of transport and metabolism

A
  • exogenous lipid pathways
  • endogenous lipid pathways
  • reverse cholesterol transport
131
Q

triglycerides

A

Triglycerides = energy
Chylomicrons, created in the gut, deliver triglycerides to muscle & adipose tissue (where converted to NEFA)
VLDLs, synthesized in liver, also deliver triglycerides to muscle & adipose tissue (again converted to NEFA)

132
Q

cholesterol

A

Cholesterol = essential building block & precursor*
Liver is the master organ: synthesis, secretion, uptake, excretion
Delivered to peripheral tissues via LDL
Uptake from circulation via remnants, IDL, LDL, HDL
Returned to liver (from peripheral tissues) via HDL

133
Q

lipid driven CV disease

A

inherited disorders of lipoprotein metabolism eg familial hypercholesterolaemia (FH)

Autosomal dominant
Mutation in LDL receptor 
Common ~1:500 to 1:200 
High LDL-C levels 
Untreated leads to premature CHD onset:
~50% men by 55 yr, ~33% women by 60 yr
Statin treatment shown to reduce CVD risk to that of general population
134
Q

prevention of CV disease

A
primary prevention (individuals without disease)
secondary prevention (patients with disease)
135
Q

drugs for CV disease

A

ACE-inhibitor, Beta-blocker – reduce post-MI mortality
Aspirin + Clopidogrel – reduce CVD recurrence & mortality
Statins – reduce CVD recurrence & mortality

136
Q

lipid lowering drugs -effects

A

statins - reduce LDL-C
ezetimibe - reduce LDL-C
Fibrates - reduce VLDL, increase HDL

137
Q

lipid lowering drugs - MOA

A

statins - HMG-CoA reductase inhibitors
ezetimibe - inhibit chol absorption in S. Intestine
fibrates - stimulates PRAR (alpha) - a nuclear transcription factor

138
Q

next generation of lipid-lowering drugs

A

PCSK9-inhibitors

  • Monoclonal antibodies, delivered by fortnightly s/c injection
  • Alirocumab, Evolocumab
  • Capable of ~60% reduction of LDL-C (as adjunct to statin)
139
Q

sinus arrhythmia

A
Sinus node fires at a variable rate
• Speeds up during inspiration
• Slows down during expiration
• Effect caused by variations in vagus nerve
activity (parasympathetic)
140
Q

sinus tachycardia

A
• Sinus node fires > 100 per minute
• Physiological causes:
– anxiety, exercise
• Pathological causes:
– fever, anemia, hyperthyroidism, heart failure
– many others
141
Q

sino-atrial disease

A

Mixture of sinus tachycardia, bradycardia

and atrial ‘ectopic’ beats, atrial fibrillation

142
Q

sinus bradycardia

A
• Sinus node fires < 60 per minute
• Physiological causes:
– Sleep, athletic training
• Pathological causes:
– hypothyroidism
– hypothermia
– sinus node disease
– raised intracranial pressure, many others
143
Q

AV nodal block

A
causes - 
sino-atrial disease
• coronary heart disease
• aortic valve disease
• damage during heart surgery
• drugs
– beta-blockers
– digoxin
– calcium channel blockers

treatment-
• Remove any triggering cause (e.g. drugs)
• atropine or isoprenaline (acute treatment)
• permanent pacemaker

144
Q

atrial flutter / fibrillation

A
causes -
• sino-atrial disease
• coronary heart disease
• valve disease (esp. mitral valve)
• hypertension
• cardiomyopathy
• hyperthyroidism
• pneumonia, lung pathology

treatment -
drug to block AV node and therefore limit
heart rate (e.g. digoxin or beta-blocker)
• electrical cardioversion
• catheter ablation

145
Q

ventricular tachycarida / fibrillation

A
• defibrillation
• antiarrhythmic drugs
• remove any triggering cause
• implantable defibrillator for some
patients
146
Q

epidemiology of venous thromboembolism

A

 Incidence: 1 per 1000 per annum
 May present as sudden death (up to 30% of
pulmonary embolism)
 30% develop recurrent venous thrombosis in 10 years
 28% develop post thrombotic syndrome
 Mortality of promptly diagnosed and adequately
treated pulmonary embolism (PE) is 2%

147
Q

venous thrombosis

A

Deep venous thrombosis (DVT)
 Pulmonary embolus (PE)
 Cerebral, mesenteric, axillary, splanchnic,
splenic

148
Q

lower limb dvt - clinical features

A

 Pain, swelling, increased temperature of limb,
dilatation of superficial veins
 Usually unilateral
 May be bilateral if thrombosis sited in inferior
vena cava
 Differential diagnosis: calf haematoma, ruptured
Baker’s cyst, cellulitis

149
Q

testing for dvt

A

contrast venography
venous ultrasonography - USS
D-Dimer test

150
Q

venous ultrasonography (USS)

A

 Non-compressibility of the common femoral vein or
popliteal vein are diagnostic of DVT
 Compression B-mode ultrasonography +/- colour
duplex imaging: sensitivity 95%, specificity 96%
for diagnosis of symptomatic proximal DVT
 But sensitivity and specificity of 60-70% for
isolated calf vein thrombosis

151
Q

pulmonary embolism - clinical features

A

Depends on number, size and distribution of
emboli
 Collapse, faintness, crushing central chest pain
 Pleuritic chest pain
 Difficulty breathing
 Haemoptysis
 Exertional dyspnoea

152
Q

diagnosis of PE

A
Chest X-ray (to exclude other pathology)
 Electrocardiogram (ECG)
 Arterial blood gases
 D-dimer
 Ventilation Perfusion (V/Q) scan
 CT-pulmonary angiogram
 Echocardiogram
153
Q

1 - rapid initial anticoagulation

A

 parenteral anticoagulant : heparin, low molecular weight
heparin, fondaparinux, OR
 direct oral anticoagulant

Aim: to reduce the risk of thrombus extension and
fatal pulmonary embolism

154
Q

2 - extended anticoagulation therapy

A

 orally active anticoagulant : vitamin K antagonist
 OR direct oral anticoagulant

Aim: to prevent recurrent thrombosis and
chronic complications such as post-phlebitic
syndrome

155
Q

management of VTE - traditional way

A

Give LMWH or UFH for a minimum of 5 days if
uncomplicated thrombosis; or for 7 days or longer if
extensive disease

Start warfarin therapy on day 1

Overlap with LMWH or UFH until INR* is 2.0 for 2
days (INR refers to International Normalised Ratio)

156
Q

direct oral anticoagulants (DOACs)

A

Refer to as “DOACS”

Used for VTE over past few years

Dabigatran, Rivaroxaban, Edoxaban & Apixaban
licensed in UK for treatment of acute DVT

Enables rapid initial anticoagulation orally

Then continue a maintenance dose for 6 months, or
longer for secondary prevention of VTE

Apixaban and Rivaroxaban do not need any overlap
with heparin – big advantage in outpatient setting

157
Q

investigation of procoagulant tendency

A
Full Blood Count
 Antithrombin
 Protein C
 Free protein S
 Antiphospholipid antibodies and lupus anticoagulant
 Thrombin time/reptilase time
158
Q

heparins

A

 Unfractionated
 Low-molecular weight heparin

 biological
product derived from porcine intestine

 Binds antithrombin and potentiates its inhibitory
action towards factor Xa and thrombin

159
Q

unfractionated heparin (UFH)

A

UFH is a heterogeneous group of
molecules with a range in MW from 3000
to 30,000D

Unpredictable anticoagulant
response due to binding to
plasma proteins

Monitoring required by
activated partial
thromboplastin time (APTT)

continuous IV infusion or 2x a day

risk of osteoporosis and HIT

reverse with protamine

160
Q

low molecular weight heparin (LMWH)

A

Produced by enzymatic or chemical depolymerisation of UFH with a
mean MW of 5000; due to the reduction in chain length there is
reduced capacity to inhibit thrombin compared with UFH.

Better bioavailability, more predictable anticoagulant response and
dose-dependent renal clearance. No lab monitoring usually necessary.

once daily dosing

reduced risk of osteoporosis, and HIT

cannot be reversed

161
Q

coumarins eg warfarin

A

Inhibit vit K dependent carboxylation of factors II,
VII, IX and X in the liver

Causes a relative deficiency of these coagulation
factors

Monitored by the International Normalised Ratio (INR),
derived from the prothrombin time (PT)

Takes around 5 days to establish maintenance dosing

Loading regimens assist early dosing

Individual dose for each patient;

racial differences reflect natural occurring polymorphisms in CYP2C9 and VKORC1 genes

Dietary intake of vit K also affects warfarin dose

many drug interactions

162
Q

reversal of warfarin

A
Management depends on whether the
patient is bleeding or not
 National reversal policies
 Vitamin K – oral or intravenous routes
 Reverse by administering the deficient
clotting factors
 Tendency to use factor concentrate
(factor II, IX and X) in place of fresh
frozen plasma (prothrombin complex
concentrate, “PCC”)
163
Q

DOACs - indications

A

Treatment of deep vein thrombosis and pulmonary
embolism nd PE
 Prevention of cardioembolic events in patients with
atrial fibrillation

 Benefits over warfarin:
 MORE PREDICTABLE ANTICOAGULANT PROFILE
 FEWER DRUG AND FOOD INTERACTIONS
 WIDER THERAPEUTIC WINDOW COMPARED TO WARFARIN
 ORAL ADMINISTRATION
 NO NEED FOR MONITORING
 SIMPLE DOSING
164
Q

reversal of DOACs

A

Antidotes being developed
 New antidote now in use for reversing dabigatran (IDARUCIZAMAB)
 For Xa-inhibitors - basic measures:
 Determine how long since last dose
 Start standard resuscitation measures
 Moderate to severe bleeding
 Local measures
 Fluid replacement
 Consider fresh frozen plasma or platelets
 Antifibrinolytic inhibitors
 Consider use of factor concentrates if extreme bleeding

165
Q

principles of heamostasis

A

Platelets - normal number, normal
function
 Functional coagulation cascade
 Normal vascular endothelium

166
Q

generation of the haemostatic plug

A

PLATELET ADHESION

  • PLATELET ACTIVATION / SECRETION
  • PLATELET AGGREGATION

The conversion of fibrinogen to fibrin by thrombin,
and polymerisation of fibrin stabilises the platelet
thrombus, resulting in a platelet-fibrin (“white”) clot

167
Q

reduced number of platelets

A

Thrombocytopenia (TP): long list of causes
 bone marrow failure
 peripheral consumption (e.g. immune TP,
disseminated intravascular coagulation (DIC), druginduced)

168
Q

abnormal platelet function

A

Most commonly drugs such as aspirin,
clopidogrel
 Renal failure: uraemia causes platelet
dysfunction

169
Q

abnormal vessel wall

A

Scurvy

Ehlers Danlos syndrome

170
Q

abnormal interaction between platelets and vessel wall

A

Von Willebrand disease

171
Q

drugs that inhibit platelet function

A

Aspirin and COX inhibitors
 Reversible COX inhibitors eg. NSAIDs
 Dipyridamole - inhibits phosphodiesterase
 Thienopyridines - inhibit ADP-mediated activation, eg clopidogrel
 Integrin GPIIb/IIIa receptor antagonists

172
Q

coagulation cascade. - waterfall theory

A
(intrinsic)
XII -> XIIa
XI -> XIa
IX -> IXa VIIIa
II - Va Xa - > IIa.   (X--> Xa ^^^ = extrinsic P - VIIa TF)
fibrinogen -> fibrin (common pathway)
173
Q

why waterfall theory fails to reflect haemostasis

A

Patients with fXII deficiency do not bleed
• Patients with fVII deficiency bleed abnormally
Patients with fVIII and fIX deficiency have severe
hemorrhagic diathesis despite a normal extrinsic
coagulation pathway
• Patients with fXI deficiency have a variable and mild
bleeding diathesis

174
Q

cell based model of coagulation

A
A series of overlapping steps that lead to
coagulation:
 Initiation
 Amplification
 Propagation
 Termination
175
Q

regulation of coagulation cascade - natural inhibitors

A

TF-VIIa complex/fXa inhibited by TFPI, tissue
factor pathway inhibitor
 Thrombin and fXa activity inhibited by
Antithrombin
 Protein C pathway inhibits fVa and fVIIIa

176
Q

prothrombin time - PT

A

Measured in seconds
 Reflects the ‘extrinsic pathway’
and the ‘common pathway’

177
Q

Activated Partial
Thromboplastin Time
(APTT)’

A

Measured in seconds
 Reflects the ‘intrinsic pathway’
and the ‘common pathway

178
Q

firbrinogen

A

Measured in grams/L
 Reflects the functional
activity of the fibrinogen
protein

179
Q

haemophilia A

A
  • x linked recessive disorder
  • 1 : 5-8000 males
  • 30% sporadic mutations
  • deficiency of fVIII
  • severity is the same within diff generations
180
Q

severity of Haemophilia A

A

 Clinical severity of haemophilia correlates to fVIII level
 <1% : SEVERE : frequent haemarthroses
 2 - 10% : MODERATE : bleeding after minor trauma
 11 - 30% : MILD : bleeding after surgical challenge
 A “normal” FVIII level ranges from 50-150%

181
Q

traditional management of haemophilia

A
  • Supportive Measures
    Ice, immobilisation, rest
    • Replacement of missing clotting protein by
      Coagulation factor concentrates, Desmopressin (DDAVP) – (used to increase factor VIII levels in mild/moderate haemophilia A)
    • Novel therapies
      monoclonal antibodies, Tranexamic acid
182
Q

von willebrand disease

A

Roles of Von Willebrand Factor
 promote platelet adhesion to subendothelium at high shear
rates
 carrier molecule for FVIII

 Most common heritable bleeding disorder
 Mainly autosomal dominant inheritance
 Men and women affected
 Associated with defective primary haemostasis
 Variable reduction in Factor VIII levels
 Mucocutaneous bleeding including menorrhagia
 Post-operative and post partum bleeding

183
Q

von willebrand disease - management

A
Antifibrinolytics: tranexamic acid
 DDAVP (for type 1 vWD)
 Factor concentrates containing vWD
 Vaccination against hepatitis A and B
 Contraceptive pill for menorrhagia
184
Q

acquired coagulation disorders

A

underproduction of coagulation factors

   - liver failure
    - vit K deficiency

anticoagulants
-warfarin, DOACs,

Immune

     - acquired haemophilia, acquired VWS
      - DIC
185
Q

liver disease

A

Reduced hepatic synthesis of clotting factors

 Thrombocytopenia secondary to hypersplenism

 Reduced vitamin K absorption due to cholestatic
jaundice causing deficiencies of factors II, VII, IX & X

 Treat with plasma products and platelets to cover
procedures, and vitamin K

186
Q

the syndrome of DIC

A

 An acquired syndrome of systemic intravascular
activation of coagulation – “thrombin explosion”
 Widespread deposition of fibrin in circulation
 Tissue ischaemia and multi-organ failure
 Consumption of platelets and coagulation factors to
generate thrombin, may induce severe bleeding

187
Q

DIC - coagulation parameters

A
  • prolonged PT
  • prolonged APTT
  • low fibrinogen
  • raised d-dimers
188
Q

Stiff arteries are bad because…

A
Stiff large arteries cause a wider
pulse pressure so:
• They cause a higher systolic BP,
leading to higher stroke and
coronary risk
• They cause a lower diastole BP,
reducing coronary artery filling
189
Q

molecular mechanisms of hypertension

A

salt handling in the kidney is critical for high blood pressure

190
Q

population approaches to hypertension

A
Increase exercise
• Increase potassium intake (fruit &amp; vegetables)
• Increase nitrate intake (fruit &amp; vegetables)
• Reduce sodium/salt intake
• Reduce alcohol intake (if excessive)
• Reduce calorie intake (if excessive)
• [Reduce (saturated) fat intake]
• [Reduce smoking]
191
Q

hypertension - working definition

A

Hypertension is having a
blood pressure at which
treatment does more good
than harm”

192
Q

stages of hypertension

A

Stage 1: Clinic BP >140/90 or home BP >135/85
Stage 2: Clinic BP >160/90
Stage 3: Clinic BP >180/110

Target BP <140/90

Cardiovascular risk ≥10% - lowers treatment
threshold

193
Q

assessment of hypertension

A
History &amp; examination
• Blood pressure – home or ambulatory
• ECG – arrhythmia, AMI
• Electrolytes – low sodium or potassium
• Creatinine/eGFR – renal function
• Urate – gout
• Glucose/HbA1c – diabetes
• Lipid profile – hypercholesterolaemia
• Urinalysis – protein, glucose, blood
194
Q

drug treatment for hypertension

A

ACE inhibitor/ANGII receptor blocker (ARB)
- enalapril

Beta- (adrenoceptor) blocker
- atenolol

Calcium entry blocker
- nifedipine

Diuretic (thiazide-type)
- bendroflumethiazide

195
Q

drug treatment for hypertension - what they dp

A

• ACE inhibitors have particular benefits
– Post -MI
– Heart failure
– Diabetic nephropathy

• Beta-blockers improve outcomes in IHD*

• Calcium antagonists reduce symptoms in angina
and isolated systolic hypertension

• Diuretics (thiazide-like) have benefits in heart failure

196
Q

reasons for treatment failure

A
Poor adherence (extremely common)
• Ineffective combinations (common)
• Other drugs (e.g. NSAIDs; common)
• Inappropriately low doses (common)
• Secondary causes (uncommon: <5%)
197
Q

radiator

A

end of the arterial tree

198
Q

starling force across capillary bed

A

BP artery - 35mmHg
osmotic - 25MMg
BP vein - 16mmHg
osmotic - 25mmHg

199
Q

common arterial pathologies

A
  • Dilated = aneurysm
  • Narrowed = stenosis
  • Blocked = occluded
200
Q

uncommon arterial pathologies

A

Split = dissection
• Over sensitive = vasospasm
• Inflamed = vasculitis
• Broken = a problem!

201
Q

aneurysms

A
  • Definition = 1.5 x the normal diameter
  • Degenerative aneurysms are the most common
  • Inflammatory, mycotic (infective), traumatic can also occur
  • Connective tissue disease – Marfans
202
Q

stenosis symptoms

A
Claudication
• Pain on walking a fixed distance
• Worse uphill
• Eases rapidly when you stop
• ANGINA of the leg!
  • Short distance Claudication
  • Nocturnal pain / rest pain
203
Q

occlusion

A
Acute
• Pain (sudden onset)
• Palor
• Perishingly cold
• Parasthesia
• Pulselessness
• Paralysis
• The SIX P’s
Chronic
• Short distance claudication
• Nocturnal pain
• Pain at rest
• Numbness
• Tissue necrosis
• Gangrene
• Things falling off
204
Q

amputation

A
Median survival after
amputation is 2.25 years
• 30 day mortality of 17%
• 30% lose the other leg with 2
years
• 6000 per year in UK
205
Q

vasculitis

A

Large vessel – Takayasu’s disease – “the pulseless disease”
• Medium vessel – Giant Cell Arteritis / Polymyalgia
• Small vessel – lots of polyangiitis conditions usually involving the
kidneys

treat - steroids and immunosuppressive agents

206
Q

diabetic foot

A
Neuropathic
• Ischaemic
• Infected
• Calcified vessels
• Small vessel arterial disease
• Patients can’t see their feet (retinopathy
207
Q

charcot foot

A
end stage diabetic foot changes
• Neuropathic
• Warm (>2℃ than normal)
• AV shunting
• Multiple fractures
• “Rocker bottom” sole
208
Q

venous resevoir

A
  • 64% of the total systemic circulation is within the veins
  • 18% in the large veins
  • 21% in large venous networks such as liver, bone marrow
  • 25% in venules and medium sized veins
209
Q

venous insufficiency

A
Failure of the muscle pump
(typically calf muscle)
 fixed ankle
• Immobility
• Dependency
• Loss of muscle mass
  • Failure of the valves
  • Or both
210
Q

venous hypertension

A
  • Haemosiderin staining
  • Swollen legs
  • Itchy, fragile skin
  • “Gaiter” distribution (shinpad)
  • Risk of ulceration
211
Q

venous hypertension - treatment

A
  • Emollient to stop skin cracks
  • Compression
  • Bandages
  • Wraps
  • Stockings
  • Elevate and mobilise
212
Q

valve failure treatment

A
  • Superficial veins
  • Endothermal ablation
  • Surgical removal
  • Foam sclerotherapy
  • Adhesive occlusion
  • Compression
  • Deep veins
  • Compression
213
Q

phlegmasia and venous gangrene

A

Rare
• Often with underlying cancer
• Thrombolysis?

214
Q

porto-systemis venous system

A
• Mesenteric or ‘portal venous’
drainage is via the liver before
the heart
• Systemic circulation is returns to
the heart directly
• The two circulation systems
combine a number of points

in liver disease - portal hypertension - Porto-systemic venous anastomosis

215
Q

oncotic pressure

A
Oncotic pressure also known as colloid
osmotic pressure is induced by
protein in the blood plasma
• Low protein (albumin) states
lead to limb swelling and
oedema

if reduced -
liver failure
renal disease
malnutrition

216
Q

arterial septal defect

A
  • Flow between the two atria

- L->R shunting which may eventually switch to R->L due to RV hypertrophy-e.g. patent foramen ovale

217
Q

ventricular septal defect

A
  • Flow between the two ventricles

- Resultant L->R shunting

218
Q

tetralogy of fallot

A
  • Ventricular septal defect
  • Pulmonary valve stenosis
  • RV hypertrophy
  • Resultant R->L shunting
219
Q

how does body respond to haemorrhage

A
Decrease on intravascular volume 
venous return to the heart 
ventricular filling 
cardiac output 
blood pressure 
renal perfusion 
capillary hydrostatic pressure
220
Q

hypovaeleamic shock

A

hypotension, reduction in renal perfusion
– lower urine output, lower cerebral perfusion
– confusion, unconsciousness

221
Q

ST elevation linked with what kind of MI

A

V1 and V2 - septal

V3 and V4 - anterior

I, aVL, V5 and V6 – lateral

II, III and aVF – inferior

aVR - non

222
Q

cardiac troponin

A

Troponin complex is 1:1:1 of three regulatory proteins (TnT, TnI, TnC)

Exclusively present in striated muscle

Regulates the interaction between actin and myosin

Cardiac specific forms exist, denoted as cTnI, cTn

223
Q

methmaemoglobin

A

when one or more iron atoms has been oxidized from ferrous to ferric state

produces super oxide O2- which is a dangerous free radical – superoxide dismutase converts this to hydrogen peroxide which catalase then breaks down to O2.

Methaemoglobin reductase reduces this back to Hb

Methaemoglobinaemia is when a mutation stabilizes methaemoglobin and the reductase cannot keep up causing elevated levels in the blood